NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

Buyer: NHS England

Deadline

Not available — this notice may describe a possible future opportunity.

Region

Not specified

Value

£19,595,208

Type

Award,contract

SME fit

—

Duration

—

Description

NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. Offer reference number: CM/PHG/24/5716 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Periods of call-offs under the framework agreement: CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Awarded to

Zentiva Pharma UK Ltd £19,595,208 Viatris UK Healthcare Limited £19,595,208 Teva UK Limited £19,595,208 SUN PHARMA UK LIMITED £19,595,208 Wockhardt UK Limited £19,595,208 Thornton and Ross Ltd £19,595,208 Milpharm Ltd £19,595,208 Lipomed AG £19,595,208 Amarox Limited £19,595,208 ACCORD-UK LTD £19,595,208 Reig Jofre UK limited £19,595,208

Quick actions

View original notice

Key details

CPV category: —
Procurement method: Open procedure
Published: 26 Mar 2026 12:18
VCSE suitable: —

Reference

OCID: ocds-h6vhtk-051c39
Notice ID: CM/PHG/24/5716
In our database since: 17 Aug 2026